Skip to Main Content
Table 2

Serum antibodies to JCV, BKV, and SV40 and their relation to the risk of a subsequent primary malignant brain tumor, Washington County, MD, 1975–2000

Polyomavirus antibodiesCasesControlsMatched OR95% CI
n(%)n(%)
JCVa       
 <640 (18.2) 22 (25.0) 1.00  
 640 or 2560 22 (50.0) 41 (46.6) 1.44 (0.57–3.64) 
 ≥10240 14 (31.8) 25 (28.4) 1.49 (0.55–4.07) 
 ≥640 36 (81.8) 66 (75.0) 1.46 (0.61–3.50) 
BKVa       
 <640 (18.2) 12 (13.6) 1.00  
 640 or 2560 17 (38.6) 39 (44.3) 0.61 (0.19–1.94) 
 ≥10240 19 (43.2) 37 (42.0) 0.72 (0.23–2.27) 
 ≥640 36 (81.8) 76 (86.4) 0.66 (0.22–1.95) 
SV40b       
 Negative 39 (88.6) 78 (88.6) 1.00  
 Weak positivec (2.3) 4d (4.5) 0.45 (0.04–4.82) 
 Positivec (9.1) (6.8) 1.33 (0.35–5.11) 
 Positivee (11.4) 10d (11.4) 1.00 (0.30–3.32) 
Polyomavirus antibodiesCasesControlsMatched OR95% CI
n(%)n(%)
JCVa       
 <640 (18.2) 22 (25.0) 1.00  
 640 or 2560 22 (50.0) 41 (46.6) 1.44 (0.57–3.64) 
 ≥10240 14 (31.8) 25 (28.4) 1.49 (0.55–4.07) 
 ≥640 36 (81.8) 66 (75.0) 1.46 (0.61–3.50) 
BKVa       
 <640 (18.2) 12 (13.6) 1.00  
 640 or 2560 17 (38.6) 39 (44.3) 0.61 (0.19–1.94) 
 ≥10240 19 (43.2) 37 (42.0) 0.72 (0.23–2.27) 
 ≥640 36 (81.8) 76 (86.4) 0.66 (0.22–1.95) 
SV40b       
 Negative 39 (88.6) 78 (88.6) 1.00  
 Weak positivec (2.3) 4d (4.5) 0.45 (0.04–4.82) 
 Positivec (9.1) (6.8) 1.33 (0.35–5.11) 
 Positivee (11.4) 10d (11.4) 1.00 (0.30–3.32) 
a

Antibody titers measured by ELISA.

b

Antibodies measured by plaque neutralization assay.

c

Weak positive is defined as positive at 1:10 serum dilution and negative at 1:40 dilution; positive is defined as positive at both dilutions.

d

Includes one specimen that was positive at the 1:10 dilution but could not be interpreted at the 1:40 dilution.

e

This positive category includes both weak positives and positives.

Close Modal

or Create an Account

Close Modal
Close Modal